SYNCONA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 110.6 GBX | -0.36% |
|
-.--% | -10.37% |
| 17/05 | Syncona notes Autolus's first quarter loss widens amid higher costs | AN |
| 09/05 | Syncona's Freeline gets positive results for Gaucher disease | AN |
| Sales 2024 * | 27.5M 35.03M 2.91B | Sales 2025 * | 27.5M 35.03M 2.91B | Capitalization | 718M 915M 75.94B |
|---|---|---|---|---|---|
| Net income 2024 * | -70M -89.18M -7.4B | Net income 2025 * | 127M 162M 13.43B | EV / Sales 2024 * | 26.1 x |
| Net cash position 2024 * | 699K 891K 73.95M | Net cash position 2025 * | 779K 992K 82.38M | EV / Sales 2025 * | 26.1 x |
| P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
5.47
x | Employees | 1,208 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syncona Limited
More press releases
| 1 day | -0.36% | ||
| 1 month | -9.34% | ||
| 3 months | -13.05% | ||
| 6 months | -12.78% | ||
| Current year | -10.37% |
1 week
110.00
114.00
1 month
106.49122.80
Current year
106.49131.94
1 year
105.00160.80
3 years
105.00224.50
5 years
105.00280.00
10 years
105.00306.50
| Managers | Title | Age | Since |
|---|---|---|---|
Annabel Clark
IRC | Investor Relations Contact | - | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 01/22/01 | |
Virginia Holmes
BRD | Director/Board Member | 64 | 01/21/01 |
Kemal Malik
BRD | Director/Board Member | 61 | 15/20/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 110.6 | -0.36% | 704,858 |
| 30/24/30 | 111 | +0.73% | 707,903 |
| 29/24/29 | 110.2 | -0.36% | 2,149,660 |
| 28/24/28 | 110.6 | -.--% | 1,142,223 |
Delayed Quote London S.E., May 31, 2024 at 09:05 pm IST
More quotes
Syncona Limited is a Guernsey-based closed-ended investment company. The Companyâs investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.
Sector
Investment Holding Companies
Calendar
20/06/2024
- Q4 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.106
GBP
Average target price
2.353
GBP
Spread / Average Target
+112.78%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.37% | 914M | |
| +21.90% | 82.45B | |
| +67.98% | 18.75B | |
| +11.28% | 17.71B | |
| +13.41% | 15.21B | |
| -2.77% | 12.55B | |
| +1.93% | 11.37B | |
| +4.32% | 10.59B | |
| -1.43% | 9.83B | |
| +30.12% | 9.77B |
- Stock Market
- Equities
- BACT Stock
